Clinical trials: Molecular Targeted Therapies
Advanced Malignant Solid Neoplasm
MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations
This phase II trial studies molecular profiling-based assignment of cancer therapy (MPACT) in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with…
- Trial name
- NCT01827384
- Testing
- Adavosertib, Carboplatin, Everolimus
- Where
- 8 sites in United States
- Volunteers
- 208 people
- Sponsor
- National Cancer Institute (NCI)
Central Nervous System Neoplasms, Pediatric Cancer
Pediatric Prospective Personalized Immune and Target Identification Trial
PPROSPERITIT is a prospective clinical study assessing the use of comprehensive molecular profiling to define the best matching targeted and immune treatment for relapsed, refractory or very high risk pediatric CNS tumors.
- Conditions
- Central Nervous System Neoplasms, Pediatric Cancer, GEN1 Gene Mutation, Tumor, Brain
- Trial name
- PPROSPERITIT (NCT04859543)
- Testing
- FoundationOneHeme
- Where
- 3 sites in Austria, Czechia
- Volunteers
- 80 people
- Sponsor
- Masaryk University
Hepatocellular Carcinoma (HCC)
Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without HAIC for Unresectable HCC With Portal Vein Tumor Thrombosis
Anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors (VEGF/TKI-ICI) plus Immune checkpoint inhibitors (ICIs) are recommended for patients with unresectable hepatocellular carcinoma (HCC) with PVTT in China.
- Trial name
- NCT06881433
- Where
- China
- Volunteers
- 1,649 people
- Sponsor
- Zhongda Hospital
Cancer
Identification of Molecular Biomarkers for Cancer Target Therapy Efficacy
This is a prospective trial for a computation-based efficacy prediction method for anticancer target therapies. The original computational algorithm utilizes individual transcriptome data of a cancer sample and assesses changes…
- Trial name
- NCT03724097
- Testing
- RNA sequencing, Transcriptome analysis, target drug with the score above 0,1
- Where
- 7 sites in United States, Russia
- Volunteers
- 200 people
- Sponsor
- OmicsWay Corp.
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma
- Trial name
- NCT02465060
- Testing
- Adavosertib, Afatinib, Afatinib Dimaleate
- Where
- 1,410 sites in United States, Guam and 1 more
- Volunteers
- 6,452 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies
You are being asked to take part in this study because you have prostate cancer that has spread to other parts of the body. This is an investigational study. Prednisone is FDA-approved and commercially available.
- Trial name
- NCT01254864
- Testing
- Abiraterone Acetate, Prednisone, Sunitinib
- Where
- United States
- Volunteers
- 190 people
- Sponsor
- M.D. Anderson Cancer Center
Biliary Tract Neoplasms
Personalized Medicine for Advanced Biliary Cancer Patients
The object of this trial is to evaluate whether the introduction of a targeted therapy after 4 cycles of the current standard-of-care treatment for advanced biliary cancer is superior to continuing with the standard treatment.
- Trial name
- SAFIR-ABC10 (NCT05615818)
- Testing
- Futibatinib, Ivosidenib, Zanidatamab
- Where
- 69 sites in Belgium, France and 1 more
- Volunteers
- 800 people
- Sponsor
- UNICANCER
Malignant Solid Tumor
A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.
This trial is a multicenter, open-label, biology driven, phase II study using a sequential Bayesian design, aiming to assess the efficacy and safety of different Matched Targeted Therapy (MTT) in independent and parallel cohorts…
- Trial name
- MegaMOST (NCT04116541)
- Testing
- HDM201, Ribociclib, Cabozantinib
- Where
- 13 sites in France
- Volunteers
- 455 people
- Sponsor
- Centre Leon Berard
Epithelial Ovarian Cancer, Ovarian Cancer
PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer
This study is the phase IV, open-label, clinical trial to determine the efficacy of niraparib maintenance therapy in BRCA1/2 wild-type, advanced-stage, low-risk, primary ovarian cancer patients.
- Conditions
- Epithelial Ovarian Cancer, Ovarian Cancer, Ovarian Cancer Stage III, Ovarian Cancer Stage IV
- Trial name
- POLO (NCT05187208)
- Testing
- Niraparib
- Volunteers
- 102 people
- Sponsor
- Seoul National University Hospital
Metastatic Melanoma
Vemurafenib Plus Cobimetinib in Metastatic Melanoma
This is a single arm explorative phase II clinical trial in 90 subjects with advanced stage melanoma harbouring a BRAFV600 mutation.
- Trial name
- REPOSIT (NCT02414750)
- Testing
- Vemurafenib plus cobimetinib, Positron Emission Tomography, Tissue sampling
- Where
- 10 sites in Netherlands
- Volunteers
- 78 people
- Sponsor
- Netherlands Working Group on Immunotherapy of Oncology
Clear Cell Sarcoma of the Kidney, Recurrent Renal Cell Carcinoma
Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of dalteparin when given together with sunitinib malate in treating patients with kidney cancer that has spread to other parts of the body or cannot be removed by surgery.
- Conditions
- Clear Cell Sarcoma of the Kidney, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT01061411
- Testing
- Dalteparin, Pharmacological Study, Sunitinib Malate
- Where
- 4 sites in United States, Netherlands
- Volunteers
- 16 people
- Sponsor
- Roswell Park Cancer Institute
Breast Cancer
Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer
The purpose of this study is to learn why certain drugs stop working in patients.In lab studies, tumors become resistant in several ways. Specific molecules seem to change and this may be why therapy stops working.
- Trial name
- NCT00897702
- Testing
- Blood draw, immunoenzyme technique, biopsy
- Where
- 7 sites in United States
- Volunteers
- 269 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
This clinical trial is looking at a drug called alectinib. Alectinib is approved as standard of care treatment for adult patients with certain types of lung cancer.
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT05770037)
- Testing
- Alectinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
This clinical trial is looking at a drug called atezolizumab. Atezolizumab is approved as standard of care treatment for adult patients with urothelial cancer, non-small cell lung cancer, extensive-stage small cell lung cancer…
- Conditions
- Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT05770102)
- Testing
- Atezolizumab
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma
Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure
This is a prospective phase II clinical trial to evaluate the efficacy and safety of apatinib and camrelizumab in recurrent or metastatic nasopharyngeal carcinoma who failed at least the first-line treatment.
- Conditions
- Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma, Chemotherapy Effect
- Trial name
- NCT04586088
- Testing
- Apatinib plus Camrelizumab
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Sun Yat-sen University
Renal Cell Carcinoma
Observational Study Evaluating The Efficacy And Effects On Quality Of Life Of Targeted Treatments Following TKIs In mRCC
Metastatic renal cell carcinoma (mRCC) is the most common malignant tumour of the kidneys. Targeted therapies, which were recently introduced in the treatment of mRCC, have become the standard treatment in these patients.
- Trial name
- NCT02315755
- Where
- 19 sites in Turkey (Türkiye)
- Volunteers
- 102 people
- Sponsor
- Pfizer
Solid Tumor
A MolEcularly Guided Anti-Cancer Drug Off-Label Trial
This is a prospective, open-label, non-randomized combined basket- and umbrella trial divided in two parts; a limited feasibility-oriented part 1 including 154 patients and 3 treatment cohorts and part 2 that will include an…
- Trial name
- MEGALiT (NCT04185831)
- Testing
- Atezolizumab, Everolimus, Cobimetinib
- Where
- 3 sites in Sweden
- Volunteers
- 167 people
- Sponsor
- Uppsala University Hospital
Neoplasms, Solid Tumors
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available…
- Conditions
- Neoplasms, Solid Tumors, Biliary Cancer, Salivary Cancer
- Trial name
- NCT02091141
- Testing
- Trastuzumab, Pertuzumab, Erlotinib
- Where
- 60 sites in United States
- Volunteers
- 673 people
- Sponsor
- Genentech, Inc.
Solid Tumors
Target Therapies Resistance Molecular Profiling in Patients With Neoplastic Disease
The main purpose of this study is to define the molecular profile of selected solid tumors. From each participants will be collected biological materials for molecular analysis, including saliva, blood and vital tumor tissue…
- Trial name
- PROFILING (NCT03347318)
- Where
- 15 sites in Italy
- Volunteers
- 2,500 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Mitral Regurgitation
Molecular Mechanisms of Mitral Regurgitation-Aim 2
The investigators hypothesize that MR in humans is characterized by adrenergic overdrive, reactive nitrogen species, and an antifibrotic phenotype that relate to the severity of adverse LV remodeling prior to surgery and outcome…
- Trial name
- P1A2 (NCT01052532)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Alabama at Birmingham